Key Highlights
- Kodiak Sciences fell on Friday with no company-specific news found, after its stock nearly tripled over September, climbing from about $37 on September 1 to about $104 on October 1.
- The September surge followed positive Phase 3 DAYBREAK trial results for Zenkuda, also known as tabirafusp-ted, in wet age-related macular degeneration, released September 28.
- Wet AMD is a leading cause of vision loss in older people, treated with eye injections, and drugs requiring less frequent injections are highly sought after to reduce patient burden.
- Health care was the only one of the eleven S&P 500 sectors to close lower on Friday, with Integra LifeSciences and Foghorn Therapeutics also among the sector's decliners.
Kodiak Sciences (NASDAQ:KOD) slipped on Friday with no new company news, as traders appeared to lock in gains after the eye-disease drug developer nearly tripled in a month. Shares fell on Friday, October 2, as traders appeared to take profits after a spectacular run in September. Kodiak was listed among the day's notable mid-cap decliners, based on intraday trading. Its closing price could not be confirmed. No company-specific news was found for the day. The pullback followed a powerful rally. Kodiak's stock nearly tripled over September, climbing from about $37 on September 1 to about $104 on October 1.
What Drove the September Rally
Kodiak develops treatments for retinal diseases, the conditions that can cause vision loss in older adults and people with diabetes. Its September surge followed positive results from DAYBREAK, a Phase 3 trial of its drug Zenkuda, also known as tabirafusp-ted, in wet age-related macular degeneration. The data were released on September 28.
Wet AMD is one of the leading causes of vision loss in older people. It is treated with injections into the eye, and drugs that can work longer between injections are highly sought after because they reduce the burden on patients.
Late-stage trial success is one of the biggest events in a biotech company's life. It can transform how investors value a drug developer almost overnight, which helps explain the size of Kodiak's run.
Why a Pullback Is Not Unusual
After a move that large, it is common for some investors to sell and lock in gains, especially in the absence of fresh news. Profit-taking can push a stock lower even when nothing has changed about the company's prospects.
The stock's huge gains over roughly the past year drew fresh attention on Friday morning. Attention like that can bring in new buyers, but it can also prompt existing holders to cash out.
Volatility is typical in biotech, where stocks often swing sharply around trial readouts, regulatory steps and financing.
Health Care Lagged on Friday
Kodiak's decline came on a weak day for health care, which was the only one of the eleven S&P 500 sectors to close lower, though only barely.
Elsewhere in the sector, Integra LifeSciences tumbled after cutting its outlook, while Foghorn Therapeutics extended losses after the end of a collaboration with Eli Lilly. On the upside, Nautilus Biotechnology and ImmunityBio posted strong gains.
A Broad Market Rally
The overall market rose after a weak jobs report. The US added only 29,000 jobs in September, far below the forecast of about 84,000. That sharply cut odds of another Federal Reserve rate hike in October, after the Fed raised rates on September 16 for the first time since 2023.
The Nasdaq Composite rose 319.27 points to 27,190.86, touching an intraday all-time high but not setting a record close. The Nasdaq-100 notched a record close. Treasury yields reversed from early declines to close higher, with the 10-year near its highest level since 2002.
Watching for Zenkuda's Next Regulatory Steps
Investors will be looking for Kodiak's next steps with Zenkuda, including any timeline for regulatory filings and further detail from the DAYBREAK trial. Medical conference presentations and analyst updates after the September data could also move the stock. Given how far the shares have climbed, further swings are possible as the market settles on a new valuation. The Fed's October 27 to 28 meeting will shape the broader mood toward biotech.






Please wait processing your request...